Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04091737
Other study ID # CSL200_1001
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date October 2, 2019
Est. completion date May 5, 2021

Study information

Verified date June 2021
Source CSL Behring
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease. The primary objectives of this study are to evaluate the safety of the following: collection of CD34+ hematopoietic stem / progenitor cells by apheresis after mobilization with plerixafor, reduced intensity conditioning with melphalan, and administration of CSL200.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date May 5, 2021
Est. primary completion date May 5, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Diagnosis of sickle cell disease with the homozygous HbS homozygous genotype (HbSS) or an HbSß thalassemia variant (ie, HbSß0 thalassemia or HbSß+ thalassemia) genotype, confirmed by hemoglobin studies. - Fetal hemoglobin (HbF) = 15%. - Severe sickle cell disease symptomatology, defined as any one or more of the following: 1. = 2 episodes of acute chest syndrome in the last 2 years. 2. = 3 episodes of severe pain events requiring a visit to a medical facility and treatment with opioids in the last 2 years. 3. > 2 episodes of recurrent priapism in the last 2 years. 4. Red-cell alloimmunization (> 2 antibodies) during long-term transfusion therapy (lifetime history). 5. Chronic transfusions for primary or secondary prophylaxis (lifetime history). 6. Trans-thoracic echocardiograph evidence of tricuspid valve regurgitant jet velocity = 2.7 m/sec (lifetime history). 7. Clinically significant neurologic event (eg, ischemic stroke) or any neurological deficit lasting > 24 hours. - Not eligible for human leukocyte antigen (HLA)-matched hematopoietic stem cell transplantation, defined as follows: no medically eligible, available, and willing 10/10 matched HLA-identical sibling donor, unless subject has declined this treatment option (as documented in the informed consent form). - Not eligible for, declined, or, as judged by the investigator, failed therapy with hydroxyurea and if still on hydroxyurea is able to interrupt hydroxyurea starting at the beginning of the transfusions, before mobilization and apheresis. Exclusion Criteria: - Hypoxanthine-guanine phosphoribosyl transferase (HPRT) deficiency. - Thiopurine S-methyltransferase (TPMT) deficiency. - Alpha thalassemia. - Inadequate bone marrow function, defined as at least 1 of the following: 1. Absolute neutrophil count < 1000/µL. 2. Platelet count < 120,000/µL.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human ?-globinG16D and short-hairpin RNA734
Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human ?-globinG16D and short-hairpin RNA734 in a bag for infusion Plerixafor to mobilize hematopoietic stem cells prior to each apheresis Single dose melphalan before administration of CSL200

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (1)

Lead Sponsor Collaborator
CSL Behring

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) associated with the administration of CSL200 Adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is medically significant.
Adverse event of special interest (AESI) is defined in this study as any of the following: acute immune reactions, autoimmunity to CSL200; malignancy; predominant integration site in presence of malignancy or other abnormality.
Up to 48 weeks
Primary Number of subjects experiencing AEs, SAEs, and AESIs associated with the administration of CSL200 Up to 48 weeks
Primary Number of AEs, SAEs, and AESIs associated with the collection of CD34+ HSPCs by apheresis after mobilization with plerixafor Up to 6 weeks
Primary Number of subjects experiencing AEs, SAEs, and AESIs associated with the collection of CD34+ HSPCs by apheresis after mobilization with plerixafor Up to 6 weeks
Primary Number of AEs, SAEs, and AESIs associated with reduced intensity conditioning with melphalan Up to 3 weeks
Primary Number of subjects experiencing AEs, SAEs, and AESIs associated with reduced intensity conditioning with melphalan Up to 3 weeks
Secondary Total by-subject number of CD34+ HSPCs collected in total and in each apheresis session Collection of CD34+ HSPCs by apheresis after mobilization with plerixafor assessed by CD34+ HSPCs collected Up to 2 days
Secondary Number of subjects receiving plerixafor and number of plerixafor doses administered by subject Collection of CD34+ HSPCs by apheresis after mobilization with plerixafor assessed by plerixafor administrations Up to 2 days
Secondary Number of subjects undergoing apheresis and number of apheresis sessions by subject Collection of CD34+ HSPCs by apheresis after mobilization with plerixafor assessed by apheresis sessions Up to 2 days
Secondary The number of subjects undergoing reduced intensity conditioning with melphalan and able to receive CSL200 Reduced intensity conditioning assessed by subjects receiving melphalan 2 days
Secondary Number of subjects receiving CSL200 1 day
Secondary By-subject number of separate CSL200 drug products administered 1 day
Secondary Number of CSL200 CD34+ HSPCs/kg administered by subject and by CSL200 drug product 1 day
Secondary By-subject total number and percentage of CD34+ HSPCs transduced with CAL-H Up to 48 weeks
Secondary Vector copy number (VCN) VCN will be determined by using the average number of CAL-H vector genomes per cell Up to 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06078696 - Siplizumab for Sickle Cell Disease Transplant Phase 1/Phase 2
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT02561312 - Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Completed NCT00890396 - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Completed NCT00005277 - Cooperative Study of The Clinical Course of Sickle Cell Disease N/A
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A
Recruiting NCT02286154 - Therapeutic Response Evaluation and Adherence Trial (TREAT) N/A
Completed NCT02857023 - Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease N/A
Withdrawn NCT01925001 - Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis Phase 2
Terminated NCT00122980 - Stroke With Transfusions Changing to Hydroxyurea Phase 3
Completed NCT00246077 - Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport N/A
Completed NCT00094887 - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Phase 2
Completed NCT00035763 - Pain in Sickle Cell Epidemiologic Study N/A
Completed NCT00005300 - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease N/A
Recruiting NCT04351698 - SMILES: Study of Montelukast in Sickle Cell Disease Phase 2/Phase 3
Not yet recruiting NCT06290401 - A Socio-ecological Approach for Improving Self-management in Adolescents With SCD Phase 2
Recruiting NCT05087303 - Telemedicine for Children With Sickle Cell Disease N/A